<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Recent Innovative Health care Technology by Ruth Wilson</title>
      <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6</link>
      <description>In this post, outlines recent innovative technology that has been applied in the health care in the past 5 years.</description>
      <language>en-us</language>
      <pubDate>2022-09-26 06:11:50 UTC</pubDate>
      <lastBuildDate>2022-10-03 00:45:42 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Source Details</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313068403</link>
         <description><![CDATA[<div>PMC pubMed Central</div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 06:13:06 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313068403</guid>
      </item>
      <item>
         <title>Date Published </title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313077496</link>
         <description><![CDATA[<div>2021 Sep 29</div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 06:21:07 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313077496</guid>
      </item>
      <item>
         <title>Summary of current innovation</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313130898</link>
         <description><![CDATA[<div>mRNA technology was for the first time commercially used after emergency use authorization was given by U.S Food and Drug Administration in December 2020 to Pfizer and Moderna, to manufacture and administer mRNA Vaccines against SARS-COV2 (Levi et al..,2021). The first commercially available vaccine using mRNA Technology, that is Covid-19, has been instrumental in stemming the spread of Covid-19 in the United States and around the world and continues to be administered to the population around the globe. Further, mRNA technology is the primary candidate for cancer immunotherapy (Levi et al..,2021). Therefore, with the outbreak of Covid-19, mRNA technology is the biggest innovative technology in health care, that facilitated the manufacturing of the viable and effective Covid-19 vaccines that are still in circulation.&nbsp;<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 07:06:08 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313130898</guid>
      </item>
      <item>
         <title>Link and/or Embedded Video and Photos</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313138669</link>
         <description><![CDATA[<div>https://youtu.be/9aG36gW1-M0<br><br><br></div>]]></description>
         <enclosure url="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479312/" />
         <pubDate>2022-09-26 07:11:55 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313138669</guid>
      </item>
      <item>
         <title>Pros of mRNA Technology</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313189940</link>
         <description><![CDATA[<div>According to Rahman and Islam (2021), the pros of Covid-19 vaccines manufactured using mRNA technology are:<br>1.Adaptability.<br>2. Quickly enhance manufacturing of vaccines, with Moderna taking 7 weeks from design, manufacturing to shipment.<br>3.&nbsp; mRNA vaccines helped prevent the loss of lives and recover the economy loss.<br>4.&nbsp; Easy for nucleotide sequence tweaking for revised formulation.<br>5. Safer and cleaner than conventional vaccine technologies&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 07:52:08 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313189940</guid>
      </item>
      <item>
         <title>Cons of mRNA Technology </title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313192334</link>
         <description><![CDATA[<div>According to Rahman and Islam (2021), the Cons of the mRNA technology vaccines are:<br>1. &nbsp; Elicit stronger type 1 interferon responses leading to inflammation.<br>2. &nbsp; Adverse reactions with 9442 cases reported in the U.S as of March 2021.<br>3. Common side effects such as pain, headache, and dizziness.<br>4.&nbsp; Neurological conditions.<br>5. Autoimmune thrombosis is associated with the AstraZeneca vaccine.<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 07:54:12 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313192334</guid>
      </item>
      <item>
         <title>Opinion and Rationale</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313212082</link>
         <description><![CDATA[<div>I have the view that mRNA technology has been integral in stabilizing the health care systems not only in the United States but also around the world.&nbsp; The rise in the Covid-19 cases created an overwhelming burden on the health care systems, mortality increased with COVID-related admissions rising above capacity of the hospitals (Myers &amp; Liu, 2022). The strain, was not only on the hospital space but also on the human resource and other medical resources that covid-19 patients required (Myers &amp; Liu, 2022). The situation became worse, and economic growth was affected significantly with millions of businesses closed and millions of people rendered jobless. Amid the aforementioned challenges, mRNA technology became the savior, because it enabled the production of the mRNA vaccines that were administered, curtailing the spread of Covid-19 hence easing the strain on the health care system.&nbsp;<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 08:10:55 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313212082</guid>
      </item>
      <item>
         <title>Using Strengths </title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313231155</link>
         <description><![CDATA[<div>My top 5 strengths are positivity, developer, responsibility, restorative, and adaptability. Cognizant of my strengths and in an endeavor to build a strong team, the following are the team members: David (deliberative), Emily (focus), Sheila (Strategic), and Angelica (Analytical).&nbsp; The strengths of the team members complement each other and give assurance of the delivery of the quality finished product when all strengths are utilized effectively and optimally.&nbsp;<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 08:25:57 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313231155</guid>
      </item>
      <item>
         <title>References</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313235147</link>
         <description><![CDATA[<div>Levi, M. L., McMillan, D., Dhandha, V., Allan, J., &amp; D'ercole, F. (2021). COVID-19 mRNA vaccination, reactogenicity, work-related absences and the impact on operating room staffing: A cross-sectional study. <em>Perioperative care and operating room management</em>, <em>25</em>, 100220. <a href="https://doi.org/10.1016/j.pcorm.2021.100220">https://doi.org/10.1016/j.pcorm.2021.100220</a>.<br><br></div><div>Myers, L. C., &amp; Liu, V. X. (2022). The COVID-19 Pandemic Strikes Again and Again and Again. <em>JAMA Network Open</em>, <em>5</em>(3), e221760-e221760. <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789848">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789848</a>.&nbsp;<br><br></div><div>Rahman, M. A., &amp; Islam, M. S. (2021). Early approval of COVID-19 vaccines: Pros and cons. <em>Human Vaccines &amp; Immunotherapeutics</em>, <em>17</em>(10), 3288-3296. <a href="https://doi.org/10.1080/21645515.2021.1944742">https://doi.org/10.1080/21645515.2021.1944742</a>&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 08:29:19 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313235147</guid>
      </item>
      <item>
         <title>Title</title>
         <author>ruthwil</author>
         <link>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313260108</link>
         <description><![CDATA[<div>Recent Innovative technology in health care-mRNA Technology</div>]]></description>
         <enclosure url="" />
         <pubDate>2022-09-26 08:48:54 UTC</pubDate>
         <guid>https://padlet.com/ruthwil/4gx3g1d3zb4tjhr6/wish/2313260108</guid>
      </item>
   </channel>
</rss>
